Innate Pharma SA SEC filings IPHYF

Innate Pharma SA has 339 filings in SEC EDGAR's recent list, going back to Jan 31, 2014. Its latest annual report, Form 20-F, was filed on Apr 1, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Nov 5, 2026. The company's fiscal year ends on December 31.

Form Description Filed Period
S-8 Employee stock plan registration Sep 11, 2024 —
424B5 Prospectus supplement Feb 6, 2024 —
F-3 Shelf registration (foreign issuer) Dec 20, 2023 —
424B5 Prospectus supplement Apr 26, 2023 —
424B5 Prospectus supplement May 3, 2022 —
S-8 Employee stock plan registration Jul 12, 2021 —
F-3 Shelf registration (foreign issuer) Jan 13, 2021 —
424B4 Prospectus Oct 18, 2019 —
FWP Free writing prospectus Oct 17, 2019 —
FWP Free writing prospectus Oct 17, 2019 —
F-6/A Filing Oct 9, 2019 —
F-1/A Filing Oct 4, 2019 —
F-6 Filing Oct 3, 2019 —
F-1 Registration statement (foreign issuer) Sep 20, 2019 —

Showing 14 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
IPHA (Nasdaq), IPHYF (OTC)
Fiscal year ends
December 31
Incorporated in
France
Headquarters
Marseille
SEC filer status
Accelerated filer
SEC CIK
1598599
Former names
Innate Pharma, SA (until Jan 31, 2014)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.